Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
Scope of the Report:
This report focuses on the Benign Prostatic Hyperplasia (BPH) Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market's growth.
The worldwide market for Benign Prostatic Hyperplasia (BPH) Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
5-Alpha-Reductase Inhibitors
Market Segment by Applications, can be divided into
Men
Women
There are 15 Chapters to deeply display the global Benign Prostatic Hyperplasia (BPH) Drugs market.
Chapter 1, to describe Benign Prostatic Hyperplasia (BPH) Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, with sales, revenue, and price of Benign Prostatic Hyperplasia (BPH) Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Benign Prostatic Hyperplasia (BPH) Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Benign Prostatic Hyperplasia (BPH) Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Benign Prostatic Hyperplasia (BPH) Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Alpha-Blocker
1.2.2 Phosphodiesterase Type-5 Inhibitors
1.2.3 5-Alpha-Reductase Inhibitors
1.3 Market Analysis by Applications
1.3.1 Men
1.3.2 Women
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Astellas Pharma
2.1.1 Business Overview
2.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Eli Lilly
2.2.1 Business Overview
2.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 GlaxoSmithKline
2.3.1 Business Overview
2.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Sanofi
2.4.1 Business Overview
2.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 ADC Therapeutics
2.5.1 Business Overview
2.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Bayer HealthCare
2.6.1 Business Overview
2.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Bristol-Myers Squibb
2.7.1 Business Overview
2.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Valeant Pharmaceuticals
2.8.1 Business Overview
2.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Endo Pharmaceuticals
2.9.1 Business Overview
2.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Foresee Pharmaceuticals
2.10.1 Business Overview
2.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis by Regions
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
4.5 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5 North America Benign Prostatic Hyperplasia (BPH) Drugs by Countries
5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Countries
6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.3 UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.4 France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs by Countries
7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.5 India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8 South America Benign Prostatic Hyperplasia (BPH) Drugs by Countries
8.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs by Countries
9.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
10 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment by Type
10.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2013-2018)
10.2 Alpha-Blocker Sales Growth and Price
10.2.1 Global Alpha-Blocker Sales Growth (2013-2018)
10.2.2 Global Alpha-Blocker Price (2013-2018)
10.3 Phosphodiesterase Type-5 Inhibitors Sales Growth and Price
10.3.1 Global Phosphodiesterase Type-5 Inhibitors Sales Growth (2013-2018)
10.3.2 Global Phosphodiesterase Type-5 Inhibitors Price (2013-2018)
10.4 5-Alpha-Reductase Inhibitors Sales Growth and Price
10.4.1 Global 5-Alpha-Reductase Inhibitors Sales Growth (2013-2018)
10.4.2 Global 5-Alpha-Reductase Inhibitors Price (2013-2018)
11 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment by Application
11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2013-2018)
11.2 Men Sales Growth (2013-2018)
11.3 Women Sales Growth (2013-2018)
12 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Type (2018-2023)
12.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
Figure Benign Prostatic Hyperplasia (BPH) Drugs Picture
Table Product Specifications of Benign Prostatic Hyperplasia (BPH) Drugs
Figure Global Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Types in 2017
Table Benign Prostatic Hyperplasia (BPH) Drugs Types for Major Manufacturers
Figure Alpha-Blocker Picture
Figure Phosphodiesterase Type-5 Inhibitors Picture
Figure 5-Alpha-Reductase Inhibitors Picture
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Applications in 2017
Figure Men Picture
Figure Women Picture
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Table Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Eli Lilly Basic Information, Manufacturing Base and Competitors
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Sanofi Basic Information, Manufacturing Base and Competitors
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table ADC Therapeutics Basic Information, Manufacturing Base and Competitors
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Bayer HealthCare Basic Information, Manufacturing Base and Competitors
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Valeant Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Endo Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Foresee Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Figure Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Revenue) Market Share in 2017
Figure Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Revenue) Market Share in 2017
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2013
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2017
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2013
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2017
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2013-2018)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2013
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2016
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries 2017
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries 2017
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2017
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2017
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2013
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Figure Global Alpha-Blocker Sales Growth (2013-2018)
Figure Global Alpha-Blocker Price (2013-2018)
Figure Global Phosphodiesterase Type-5 Inhibitors Sales Growth (2013-2018)
Figure Global Phosphodiesterase Type-5 Inhibitors Price (2013-2018)
Figure Global 5-Alpha-Reductase Inhibitors Sales Growth (2013-2018)
Figure Global 5-Alpha-Reductase Inhibitors Price (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Figure Global Women Sales Growth (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Regions (2018-2023)
Figure North America Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure Europe Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure Asia-Pacific Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure South America Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure Middle East and Africa Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Type (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Application (2018-2023)
Table Distributors/Traders/ Dealers List